Tech Company Financing Transactions

AnBogen Therapeutics Funding Round

On 7/1/2024, AnBogen Therapeutics secured $7.5 million in Series A funding from KGI Venture Capital and private investors.

Transaction Overview

Announced On
7/1/2024
Transaction Type
Venture Equity
Amount
$7,500,000
Round
Series A
Investors

KGI Venture Capital (Lead Investor)

Proceeds Purpose
The company intends to use the funds to support the Phase II clinical trial of ABT-301 in combination with PD-1 inhibitors for treating microsatellite stable (MSS) metastatic colorectal cancer, which accounts for 95% of the metastatic colorectal cancer population that does not benefit from immune checkpoint inhibitors.

Company Information

Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
No.99, Lane 130, Sec. 1, Research Institute Road, Nangang Di C523
Taipei, 11571
Taiwan
Email Address
Overview
Anbogen Therapeutics is a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients. Founded by a group of exceptional scientists from National Health Research Institute, the most prestigious medical research institute in Taiwan, we are devoted to bringing the gap between research and clinical development and dedicated to creating breakthrough science that changes the life of cancer patients.
Profile
AnBogen Therapeutics LinkedIn Company Profile
Social Media
AnBogen Therapeutics Company Twitter Account
Company News
AnBogen Therapeutics News
Facebook
AnBogen Therapeutics on Facebook
YouTube
AnBogen Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Tsu-An Hsu
  Tsu-An Hsu LinkedIn Profile  Tsu-An Hsu Twitter Account  Tsu-An Hsu News  Tsu-An Hsu on Facebook
President
Joe Hsueh
  Joe Hsueh LinkedIn Profile  Joe Hsueh Twitter Account  Joe Hsueh News  Joe Hsueh on Facebook
VP - Bus. Development
Chun-Hsuan Lo
  Chun-Hsuan Lo LinkedIn Profile  Chun-Hsuan Lo Twitter Account  Chun-Hsuan Lo News  Chun-Hsuan Lo on Facebook
VP - Bus. Development
Kien-Thiam Tan
  Kien-Thiam Tan LinkedIn Profile  Kien-Thiam Tan Twitter Account  Kien-Thiam Tan News  Kien-Thiam Tan on Facebook
VP - Bus. Development
Angus Tsung-Kai Wu
  Angus Tsung-Kai Wu LinkedIn Profile  Angus Tsung-Kai Wu Twitter Account  Angus Tsung-Kai Wu News  Angus Tsung-Kai Wu on Facebook
VP - Finance
Endy Yang
  Endy Yang LinkedIn Profile  Endy Yang Twitter Account  Endy Yang News  Endy Yang on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/28/2024: Waypoint Bio venture capital transaction
Next: 7/1/2024: LiveOak Fiber venture capital transaction

 

Share this article

 


News on VC Transactions

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary